1
|
Zhang P, Cheng J, Lu Y, Zhang N, Wu X, Lin H, Li W, Wang J, Winnik MA, Gan Z, Hou Y. Hypersensitive MR angiography based on interlocking stratagem for diagnosis of cardiac-cerebral vascular diseases. Nat Commun 2023; 14:6149. [PMID: 37783733 PMCID: PMC10545789 DOI: 10.1038/s41467-023-41783-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2022] [Accepted: 09/11/2023] [Indexed: 10/04/2023] Open
Abstract
Magnetic resonance (MR) angiography is one of the main diagnostic approaches for cardiac-cerebral vascular diseases. Nevertheless, the non-contrast-enhanced MR angiography suffers from its intrinsic problems derived from the blood flow-dependency, while the clinical Gd-chelating contrast agents are limited by their rapid vascular extravasation. Herein, we report a hypersensitive MR angiography strategy based on interlocking stratagem of zwitterionic Gd-chelate contrast agents (PAA-Gd). The longitudinal molar relaxivity of PAA-Gd was 4.6-times higher than that of individual Gd-chelates as well as appropriate blood half-life (73.8 min) and low immunogenicity, enabling sophisticated micro-vessels angiography with a resolution at the order of hundred micrometers. A series of animal models of cardiac-cerebrovascular diseases have been built for imaging studies on a 7.0 T MRI scanner, while the clinical translation potential of PAA-Gd has been evaluated on swine on a 3.0 T clinical MRI scanner. The current studies offer a promising strategy for precise diagnosis of vascular diseases.
Collapse
Affiliation(s)
- Peisen Zhang
- College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China
| | - Junwei Cheng
- College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China
| | - Yijie Lu
- Department of Chemistry, University of Toronto, Toronto, ON, M5S 3H6, Canada
| | - Ni Zhang
- Department of Psychiatry, and Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China
| | - Xiaoai Wu
- Department of Psychiatry, and Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China
| | - Hua Lin
- Department of Psychiatry, and Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China
| | - Wei Li
- Department of Nanomedicine & International Joint Cancer Institute, Naval Medical University, Shanghai, 200433, China.
| | - Jian Wang
- Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100021, China
| | - Mitchell A Winnik
- Department of Chemistry, University of Toronto, Toronto, ON, M5S 3H6, Canada
| | - Zhihua Gan
- College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China.
| | - Yi Hou
- College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, 100029, China.
| |
Collapse
|
2
|
Huang Y, Hsu JC, Koo H, Cormode DP. Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle. Am J Cancer Res 2022; 12:796-816. [PMID: 34976214 PMCID: PMC8692919 DOI: 10.7150/thno.67375] [Citation(s) in RCA: 71] [Impact Index Per Article: 35.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Accepted: 11/12/2021] [Indexed: 02/07/2023] Open
Abstract
Ferumoxytol is an intravenous iron oxide nanoparticle formulation that has been approved by the U.S. Food and Drug Administration (FDA) for treating anemia in patients with chronic kidney disease. In recent years, ferumoxytol has also been demonstrated to have potential for many additional biomedical applications due to its excellent inherent physical properties, such as superparamagnetism, biocatalytic activity, and immunomodulatory behavior. With good safety and clearance profiles, ferumoxytol has been extensively utilized in both preclinical and clinical studies. Here, we first introduce the medical needs and the value of current iron oxide nanoparticle formulations in the market. We then focus on ferumoxytol nanoparticles and their physicochemical, diagnostic, and therapeutic properties. We include examples describing their use in various biomedical applications, including magnetic resonance imaging (MRI), multimodality imaging, iron deficiency treatment, immunotherapy, microbial biofilm treatment and drug delivery. Finally, we provide a brief conclusion and offer our perspectives on the current limitations and emerging applications of ferumoxytol in biomedicine. Overall, this review provides a comprehensive summary of the developments of ferumoxytol as an agent with diagnostic, therapeutic, and theranostic functionalities.
Collapse
|
3
|
Muehe AM, Yerneni K, Theruvath AJ, Thakor AS, Pribnow A, Avedian R, Steffner R, Rosenberg J, Hawk KE, Daldrup-Link HE. Ferumoxytol Does Not Impact Standardized Uptake Values on PET/MR Scans. Mol Imaging Biol 2021; 22:722-729. [PMID: 31325083 DOI: 10.1007/s11307-019-01409-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
PURPOSE Tumor response assessments on positron emission tomography (PET)/magnetic resonance imaging (MRI) scans require correct quantification of radiotracer uptake in tumors and normal organs. Historically, MRI scans have been enhanced with gadolinium (Gd)-based contrast agents, which are now controversial due to brain deposition. Recently, ferumoxytol nanoparticles have been identified as an alternative to Gd-based contrast agents because they provide strong tissue enhancement on MR images but are not deposited in the brain. However, it is not known if the strong T1- and T2-contrast obtained with iron oxide nanoparticles such as ferumoxytol could affect MR-based attenuation correction of PET data. The purpose of our study was to investigate if ferumoxytol administration prior to a 2-deoxy-2-[18F]fluoro-D-glucose [18F]FDG PET/MR scan would change standardized uptake values (SUV) of normal organs. PROCEDURES Thirty pediatric patients (6-18 years) with malignant tumors underwent [18F]FDG-PET/MR scans (dose 3 MBq/kg). Fifteen patients received an intravenous ferumoxytol injection (5 mg Fe/kg) prior to the [18F]FDG-PET/MR scans (group 1). Fifteen additional age- and sex-matched patients received unenhanced [18F]FDG-PET/MR scans (group 2). For attenuation correction of PET data, we used a Dixon-based gradient echo sequence (TR 4.2 ms, TE 1.1, 2.3 ms, FA 5), which accounted for soft tissue, lung, fat, and background air. We used a mixed linear effects model to compare the tissue MRI enhancement, quantified as the signal-to-noise ratio (SNR), as well as tissue radiotracer signal, quantified as SUVmean and SUVmax, between group 1 and group 2. Alpha was assumed at 0.05. RESULTS The MRI enhancement of the blood and solid extra-cerebral organs, quantified as SNR, was significantly higher on ferumoxytol-enhanced MRI scans compared to unenhanced scans (p < 0.001). However, SUVmean and SUVmax values, corrected based on the patients' body weight or body surface area, were not significantly different between the two groups (p > 0.05). CONCLUSION Ferumoxytol administration prior to a [18F]FDG PET/MR scan did not change standardized uptake values (SUV) of solid extra-cerebral organs. This is important, because it allows injection of ferumoxytol contrast prior to a PET/MRI procedure and, thereby, significantly accelerates image acquisition times.
Collapse
Affiliation(s)
- Anne M Muehe
- Department of Radiology, Pediatric Molecular Imaging Program, Stanford University, 725 Welch Road, Stanford, CA, 94304, USA
| | - Ketan Yerneni
- Department of Radiology, Pediatric Molecular Imaging Program, Stanford University, 725 Welch Road, Stanford, CA, 94304, USA
| | - Ashok J Theruvath
- Department of Radiology, Pediatric Molecular Imaging Program, Stanford University, 725 Welch Road, Stanford, CA, 94304, USA.,Department of Diagnostic and Interventional Radiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
| | - Avnesh S Thakor
- Department of Radiology, Pediatric Molecular Imaging Program, Stanford University, 725 Welch Road, Stanford, CA, 94304, USA
| | - Allison Pribnow
- Department of Pediatrics, Division of Hematology/Oncology, Stanford University School of Medicine, Stanford, CA, USA
| | - Raffi Avedian
- Department of Orthopedic Surgery, Lucile Packard Children's Hospital, Stanford University, Stanford, CA, USA
| | - Robert Steffner
- Department of Orthopedic Surgery, Lucile Packard Children's Hospital, Stanford University, Stanford, CA, USA
| | - Jarrett Rosenberg
- Department of Radiology, Pediatric Molecular Imaging Program, Stanford University, 725 Welch Road, Stanford, CA, 94304, USA
| | - Kristina E Hawk
- Department of Radiology, Pediatric Molecular Imaging Program, Stanford University, 725 Welch Road, Stanford, CA, 94304, USA
| | - Heike E Daldrup-Link
- Department of Radiology, Pediatric Molecular Imaging Program, Stanford University, 725 Welch Road, Stanford, CA, 94304, USA. .,Department of Pediatrics, Division of Hematology/Oncology, Stanford University School of Medicine, Stanford, CA, USA.
| |
Collapse
|
4
|
Abstract
Attenuation correction has been one of the main methodological challenges in the integrated positron emission tomography and magnetic resonance imaging (PET/MRI) field. As standard transmission or computed tomography approaches are not available in integrated PET/MRI scanners, MR-based attenuation correction approaches had to be developed. Aspects that have to be considered for implementing accurate methods include the need to account for attenuation in bone tissue, normal and pathological lung and the MR hardware present in the PET field-of-view, to reduce the impact of subject motion, to minimize truncation and susceptibility artifacts, and to address issues related to the data acquisition and processing both on the PET and MRI sides. The standard MR-based attenuation correction techniques implemented by the PET/MRI equipment manufacturers and their impact on clinical and research PET data interpretation and quantification are first discussed. Next, the more advanced methods, including the latest generation deep learning-based approaches that have been proposed for further minimizing the attenuation correction related bias are described. Finally, a future perspective focused on the needed developments in the field is given.
Collapse
Affiliation(s)
- Ciprian Catana
- Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, United States of America
| |
Collapse
|
5
|
Gholami YH, Yuan H, Wilks MQ, Maschmeyer R, Normandin MD, Josephson L, El Fakhri G, Kuncic Z. A Radio-Nano-Platform for T1/T2 Dual-Mode PET-MR Imaging. Int J Nanomedicine 2020; 15:1253-1266. [PMID: 32161456 PMCID: PMC7049573 DOI: 10.2147/ijn.s241971] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2019] [Accepted: 02/09/2020] [Indexed: 01/13/2023] Open
Abstract
Purpose This study aimed to develop a chelate-free radiolabeled nanoparticle platform for simultaneous positron emission tomography (PET) and magnetic resonance (MR) imaging that provides contrast-enhanced diagnostic imaging and significant image quality gain by integrating the high spatial resolution of MR with the high sensitivity of PET. Methods A commercially available super-paramagnetic iron oxide nanoparticle (SPION) (Feraheme®, FH) was labeled with the [89Zr]Zr using a novel chelate-free radiolabeling technique, heat-induced radiolabeling (HIR). Radiochemical yield (RCY) and purity (RCP) were measured using size exclusion chromatography (SEC) and radio-thin layer chromatography (radio-TLC). Characterization of the non-radioactive isotope 90Zr-labeled FH was performed by transmission electron microscopy (TEM). Simultaneous PET-MR phantom imaging was performed with different 89Zr-FH concentrations. The MR quantitative image analysis determined the contrast-enhancing properties of FH. The signal-to-noise ratio (SNR) and full-width half-maximum (FWHM) of the line spread function (LSF) were calculated before and after co-registering the PET and MR image data. Results High RCY (92%) and RCP (98%) of the [89Zr]Zr-FH product was achieved. TEM analysis confirmed the 90Zr atoms adsorption onto the SPION surface (≈ 10% average radial increase). Simultaneous PET-MR scans confirmed the capability of the [89Zr]Zr-FH nano-platform for this multi-modal imaging technique. Relative contrast image analysis showed that [89Zr]Zr-FH can act as a dual-mode T1/T2 contrast agent. For co-registered PET-MR images, higher spatial resolution (FWHM enhancement ≈ 3) and SNR (enhancement ≈ 8) was achieved at a clinical dose of radio-isotope and Fe. Conclusion Our results demonstrate FH is a highly suitable SPION-based platform for chelate-free labeling of PET tracers for hybrid PET-MR. The high RCY and RCP confirmed the robustness of the chelate-free HIR technique. An overall image quality gain was achieved compared to PET- or MR-alone imaging with a relatively low dosage of [89Zr]Zr-FH. Additionally, FH is suitable as a dual-mode T1/T2 MR image contrast agent. ![]()
Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use: http://youtu.be/Me_QBfX7I3s
Collapse
Affiliation(s)
- Yaser Hadi Gholami
- Faculty of Science, School of Physics, The University of Sydney, Sydney, NSW, Australia.,Sydney Vital Translational Cancer Research Centre, St Leonards, NSW, Australia.,Bill Walsh Translational Cancer Research Laboratory, The Kolling Institute, Northern Sydney Local Health District, Sydney, NSW, Australia
| | - Hushan Yuan
- Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Moses Q Wilks
- Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Richard Maschmeyer
- Faculty of Science, School of Physics, The University of Sydney, Sydney, NSW, Australia
| | - Marc D Normandin
- Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Lee Josephson
- Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Georges El Fakhri
- Gordon Center for Medical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Zdenka Kuncic
- Faculty of Science, School of Physics, The University of Sydney, Sydney, NSW, Australia.,Sydney Vital Translational Cancer Research Centre, St Leonards, NSW, Australia.,The University of Sydney Nano Institute, Sydney, NSW, Australia
| |
Collapse
|
6
|
Lillington J, Brusaferri L, Kläser K, Shmueli K, Neji R, Hutton BF, Fraioli F, Arridge S, Cardoso MJ, Ourselin S, Thielemans K, Atkinson D. PET/MRI attenuation estimation in the lung: A review of past, present, and potential techniques. Med Phys 2020; 47:790-811. [PMID: 31794071 PMCID: PMC7027532 DOI: 10.1002/mp.13943] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2019] [Revised: 07/23/2019] [Accepted: 11/20/2019] [Indexed: 12/16/2022] Open
Abstract
Positron emission tomography/magnetic resonance imaging (PET/MRI) potentially offers several advantages over positron emission tomography/computed tomography (PET/CT), for example, no CT radiation dose and soft tissue images from MR acquired at the same time as the PET. However, obtaining accurate linear attenuation correction (LAC) factors for the lung remains difficult in PET/MRI. LACs depend on electron density and in the lung, these vary significantly both within an individual and from person to person. Current commercial practice is to use a single‐valued population‐based lung LAC, and better estimation is needed to improve quantification. Given the under‐appreciation of lung attenuation estimation as an issue, the inaccuracy of PET quantification due to the use of single‐valued lung LACs, the unique challenges of lung estimation, and the emerging status of PET/MRI scanners in lung disease, a review is timely. This paper highlights past and present methods, categorizing them into segmentation, atlas/mapping, and emission‐based schemes. Potential strategies for future developments are also presented.
Collapse
Affiliation(s)
- Joseph Lillington
- Centre for Medical Imaging, University College London, London, W1W 7TS, UK
| | - Ludovica Brusaferri
- Institute of Nuclear Medicine, University College London, London, NW1 2BU, UK
| | - Kerstin Kläser
- Centre for Medical Image Computing, University College London, London, WC1E 7JE, UK
| | - Karin Shmueli
- Magnetic Resonance Imaging Group, Department of Medical Physics & Biomedical Engineering, University College London, London, WC1E 6BT, UK
| | - Radhouene Neji
- MR Research Collaborations, Siemens Healthcare Limited, Frimley, GU16 8QD, UK
| | - Brian F Hutton
- Institute of Nuclear Medicine, University College London, London, NW1 2BU, UK
| | - Francesco Fraioli
- Institute of Nuclear Medicine, University College London, London, NW1 2BU, UK
| | - Simon Arridge
- Centre for Medical Image Computing, University College London, London, WC1E 7JE, UK
| | - Manuel Jorge Cardoso
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, SE1 7EH, UK
| | - Sebastien Ourselin
- School of Biomedical Engineering & Imaging Sciences, King's College London, London, SE1 7EH, UK
| | - Kris Thielemans
- Institute of Nuclear Medicine, University College London, London, NW1 2BU, UK
| | - David Atkinson
- Centre for Medical Imaging, University College London, London, W1W 7TS, UK
| |
Collapse
|
7
|
How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach. Mol Imaging Biol 2019; 20:324-335. [PMID: 28721605 DOI: 10.1007/s11307-017-1105-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
PURPOSE To provide clinically useful gadolinium-free whole-body cancer staging of children and young adults with integrated positron emission tomography/magnetic resonance (PET/MR) imaging in less than 1 h. PROCEDURES In this prospective clinical trial, 20 children and young adults (11-30 years old, 6 male, 14 female) with solid tumors underwent 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) PET/MR on a 3T PET/MR scanner after intravenous injection of ferumoxytol (5 mg Fe/kg) and [18F]FDG (2-3 MBq/kg). Time needed for patient preparation, PET/MR image acquisition, and data processing was compared before (n = 5) and after (n = 15) time-saving interventions, using a Wilcoxon test. The ferumoxytol-enhanced PET/MR images were compared with clinical standard staging tests regarding radiation exposure and tumor staging results, using Fisher's exact tests. RESULTS Tailored workflows significantly reduced scan times from 36 to 24 min for head to mid thigh scans (p < 0.001). These streamlined PET/MR scans were obtained with significantly reduced radiation exposure (mean 3.4 mSv) compared to PET/CT with diagnostic CT (mean 13.1 mSv; p = 0.003). Using the iron supplement ferumoxytol "off label" as an MR contrast agent avoided gadolinium chelate administration. The ferumoxytol-enhanced PET/MR scans provided equal or superior tumor staging results compared to clinical standard tests in 17 out of 20 patients. Compared to PET/CT, PET/MR had comparable detection rates for pulmonary nodules with diameters of equal or greater than 5 mm (94 vs. 100 %), yet detected significantly fewer nodules with diameters of less than 5 mm (20 vs 100 %) (p = 0.03). [18F]FDG-avid nodules were detected with slightly higher sensitivity on the PET of the PET/MR compared to the PET of the PET/CT (59 vs 49 %). CONCLUSION Our streamlined ferumoxytol-enhanced PET/MR protocol provided cancer staging of children and young adults in less than 1 h with equivalent or superior clinical information compared to clinical standard staging tests. The detection of small pulmonary nodules with PET/MR needs to be improved.
Collapse
|
8
|
Büther F, Noto B, Auf der Springe K, Allkemper T, Stegger L. An artefact of PET attenuation correction caused by iron overload of the liver in clinical PET-MRI. Eur J Hybrid Imaging 2017; 1:10. [PMID: 29782579 PMCID: PMC5954667 DOI: 10.1186/s41824-017-0015-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2017] [Accepted: 10/23/2017] [Indexed: 11/10/2022] Open
Abstract
Background Attenuation correction is one of the most important steps in producing quantitative PET image data. In hybrid PET-MRI systems, this correction is far from trivial, as MRI data are not correlated to PET attenuation properties of the scanned object. Commercially available systems often employ correction schemes based on segmenting the body into different tissue classes (air, lung tissue, fat-, and water-like soft tissue), e.g. by using a dual time-point Dixon sequence. However, several pitfalls are known for this approach. Here a specific artefact of MR-based PET attenuation correction is reported, caused by misidentifying the liver as lung tissue due to iron overload. Case presentation A patient with a history of hematopoietic stem cell transplantation underwent a whole-body [18F]FDG PET-MRI scan. Markedly low liver uptake values were noted in the PET images, seemingly caused by an erroneous assignment of lung tissue attenuation values to the liver. A closer investigation demonstrated markedly low MRI intensity values of the liver, indicative of secondary hemochromatosis (iron overload) most probably due to a history of multiple blood transfusions. Manual assignment of adequate liver attenuation values resulted in more realistic PET images. Conclusions Iron overload of the liver was identified as a cause of a specific attenuation correction artefact. It remains to be seen how frequent this artefact will be encountered; however, this case highlights that attenuation maps should always be checked during PET image interpretation in hybrid PET-MRI.
Collapse
Affiliation(s)
- Florian Büther
- 1Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany.,2European Institute for Molecular Imaging, University of Münster, Münster, Germany
| | - Benjamin Noto
- 1Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany
| | | | - Thomas Allkemper
- 3Institute for Clinical Radiology, University Hospital Münster, Münster, Germany
| | - Lars Stegger
- 1Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany
| |
Collapse
|
9
|
Abstract
Nuclear imaging techniques, including primarily positron emission tomography (PET) and single-photon emission computed tomography (SPECT), can provide quantitative information for a biological event in vivo with ultra-high sensitivity, however, the comparatively low spatial resolution is their major limitation in clinical application. By convergence of nuclear imaging with other imaging modalities like computed tomography (CT), magnetic resonance imaging (MRI) and optical imaging, the hybrid imaging platforms can overcome the limitations from each individual imaging technique. Possessing versatile chemical linking ability and good cargo-loading capacity, radioactive nanomaterials can serve as ideal imaging contrast agents. In this review, we provide a brief overview about current state-of-the-art applications of radioactive nanomaterials in the circumstances of multimodality imaging. We present strategies for incorporation of radioisotope(s) into nanomaterials along with applications of radioactive nanomaterials in multimodal imaging. Advantages and limitations of radioactive nanomaterials for multimodal imaging applications are discussed. Finally, a future perspective of possible radioactive nanomaterial utilization is presented for improving diagnosis and patient management in a variety of diseases.
Collapse
Affiliation(s)
- Daiqin Chen
- Department of Radiology, University of Michigan, Ann Arbor, Michigan
- Center for Molecular Imaging, University of Michigan, Ann Arbor, Michigan; and
| | - Casey A. Dougherty
- Department of Radiology, University of Michigan, Ann Arbor, Michigan
- Center for Molecular Imaging, University of Michigan, Ann Arbor, Michigan; and
| | - Dongzhi Yang
- Department of Radiology, University of Michigan, Ann Arbor, Michigan
- Center for Molecular Imaging, University of Michigan, Ann Arbor, Michigan; and
| | - Hongwei Wu
- Department of Radiology, University of Michigan, Ann Arbor, Michigan
- Center for Molecular Imaging, University of Michigan, Ann Arbor, Michigan; and
| | - Hao Hong
- Department of Radiology, University of Michigan, Ann Arbor, Michigan
- Center for Molecular Imaging, University of Michigan, Ann Arbor, Michigan; and
- Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan
| |
Collapse
|